A new global site selection study has been released by The Boyd Company, Inc. The report compares the cost of operating a biomanufacturing plant in a series of 25 top U.S. and off-shore hubs of the biopharma industry. Operating costs are scaled to a hypothetical 300,000 sq. ft. biologics production plant employing 300 workers. The analysis includes all major geographically-variable cost factors critical to the corporate site selection process for new biomanufacturing operations. The Boyd study ...